PubMed Health⌕ Search

PubMed · 7822187

Bilateral parotid neoplasms.

Abstract

In this case, the experts come out of the starting blocks disagreeing. One expert (Dr. Myers) does not routinely use FNA, relying instead on clinical signs to suspect a malignancy. the other physicians (Drs. Robbins and Suen) obtain an FNA for each parotid mass and use the information in counseling patients. MRI is an important preoperative tool for one physician (Dr. Suen). When faced with bilateral tumors, one approach is to stage the operations to avoid possible bilateral facial nerve injury (Dr. Myers). Other approaches include operating on the larger tumor first if both are benign, the malignant tumor first if one is benign and one malignant, and on both sides under the same anesthetic if both are malignant (Dr. Robbins). The other consultant agrees with this latter approach, with the exception being that in the case of bilateral benign tumors, he would operate on the smaller side first (Dr. Suen). Regarding the role for further surgery, one expert would reoperate if there were a suspicion for residual gross tumor on the facial nerve (Dr. Robbins). The others (Drs. Myers and Suen) agree that the positive margin likely reflects microscopic disease and further surgery is not warranted. Radiotherapy is recommended by all the experts. There is no proven role for chemotherapy. There is disagreement regarding whether the facial nerve should have been removed on the left side. Two experts (Drs. Myers and Suen) agree on peeling tumor off the nerve and following with radiotherapy. However, one physician (Dr. Robbins) believes that the facial nerve should have been removed.(ABSTRACT TRUNCATED AT 250 WORDS)

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

E N Myers, K T Robbins, J Y Suen. Bilateral parotid neoplasms.. https://doi.org/10.1002/hed.2880160619

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

The case for routine use of adjuvant therapy in pancreatic cancer.

Pancreatic cancer is a devastating disease with a poor prognosis for most patients. Surgical resection remains the cornerstone of treatment, providing the only realistic hope of long-term survival. Even with optimal surgical management, 5-year survival averages 15% to 20% for resectable disease. Progress is being made, however. Currently, the benefits of postoperative therapy for resected pancreatic ductal adenocarcinoma appear clear, and recommendations for such therapy appear to us to be well justified. Additional benefit to patients awaits the development of new agents, molecular targeted drugs, and novel approaches such as immunotherapy.

Adenocarcinoma↗

Proposal for a new definition of true cardia carcinoma.

BACKGROUND AND OBJECTIVES: It remains controversial whether cardia carcinoma should be categorized and treated as esophageal cancer or gastric cancer. The purpose of this study was to develop a reasonable definition of cardia carcinoma. METHODS: Patients with Siewert type II carcinomas were divided into two subgroups: 25 patients with a tumor center within 1 cm of the esophagogastric junction (EGJ) (type IIA) and 22 patients with tumor center 1-2 cm aboral of the EGJ (type IIB). Patients with subcardia carcinomas, 40 with invasion to the EGJ (type III) and 110 without (type IIIe-), were used as controls. RESULTS: The patients with type IIB carcinomas showed no different characteristics from those with type III or type IIIe- carcinomas, except for the stage of the disease. On the other hand, those with type IIA carcinomas were associated with a higher male/female ratio, higher incidences of elevated appearance, differentiated histology, and mediastinal node metastasis, and a significantly lower survival rate as compared with patients with subcardia carcinomas. Multivariate survival analysis revealed that type IIA is a significant prognostic determinant, but that type IIB is not. CONCLUSION: Type IIA carcinomas should be treated as true cardia carcinoma; type IIB as subcardia carcinoma. Our results should be confirmed by a prospective study.

Adenocarcinoma↗

Favorable indications for hepatectomy in patients with liver metastasis from gastric cancer.

BACKGROUND: The prognosis of patients with liver metastasis from gastric cancer (LMGC) is dismal. The purpose of this study was to review our recent outcomes of hepatectomy for LMGC and to determine the suitable candidates for surgery. STUDY DESIGN: The outcomes of 37 patients with LMGC who underwent hepatectomy between 1990 and 2005 were assessed. No extrahepatic distant metastasis and feasibility of macroscopic curative resection were requisite indications for surgery. The prognostic values of clinicopathological factors were assessed by univariate and multivariate analyses. RESULTS: There was no in-hospital mortality. The median survival time and overall 5-year survival rate after hepatectomy of the patients with LMGC were 31 months and 11%, respectively. Intrahepatic recurrence following hepatectomy was found in 23 patients (62%). Variables independently associated with poor survival were bilobar metastasis (P = 0.002, CI = 1.9-16.3) and a maximum tumor diameter of >or= 4 cm (P = 0.006, CI = 1.4-7.7). The depth of the primary tumor and the timing of metastasis were not associated with survival. CONCLUSIONS: Surgical resection for LMGC may be indicated in patients with unilobar metastasis and/or tumors less than 4 cm in diameter. Synchronous metastasis is not a contraindication for hepatectomy.

Adenocarcinoma↗